Dear Grampian Health Board,

The following questions are being asked for on behalf of Novartis. The purpose of these questions is to understand the variability of treatment within your trust and in context to the rest of the country.

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:
• Bevacizumab (Avastin)
• Dacarbazine (DTIC)
• Trametinib (Mekinist)
• Dabrafenib (Tafinlar)
• Ipilimumab (Yervoy)
• Vemurafenib (Zelboraf)
• Nivolumab (Opdivo)
• Nivolumab + Ipilimumab (Opdivo + Yervoy)
• Pembrolizumab (Keytruda)
• Vemurafenib + cobimetinib (Zelboraf + Cotellic)
• Dabrafenib + Trametinib (Tafinlar + Mekinist)
• Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
• Other active systemic anti-cancer therapy [please state]
• Palliative care only

Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:
• Ipilimumab
• Ipilimumab AND Nivolumab
• Nivolumab
• Pembrolizumab
• Dabrafenib AND Trametinib
• Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
• Other active systemic anti-cancer therapy
• Palliative care only

Sincerely thank you for taking the time and resources to answer these questions.

Yours faithfully,

Ben Holdsworth